Phosphorylation status of MUS81 is a modifier of Olaparib sensitivity in BRCA2-deficient cells

Nucleic Acids Res. 2023 Jul 21;51(13):6723-6737. doi: 10.1093/nar/gkad470.

Abstract

The MUS81 complex is crucial for preserving genome stability through resolution of branched DNA intermediates in mitosis and also for the processing of deprotected replication forks in BRCA2-deficient cells. Because of the existence of two different MUS81 complexes in mammalian cells that act in M- or S-phase, whether and how the PARPi sensitivity of BRCA2-deficient cells is affected by loss of MUS81 function is unclear. Here, using a mutant of MUS81 that impairs its function in M-phase, we show that viability of BRCA2-deficient cells but not their PARPi sensitivity requires a fully-functional MUS81 complex in mitosis. In contrast, expression of a constitutively-active MUS81 is sufficient to confer PARPi resistance. From a mechanistic point of view, our data indicate that deregulated action of the mitotic active form of MUS81 in S-phase leads to the cleavage of stalled replication forks before their reversal, bypassing fork deprotection, and engaging a Polθ-dependent DSBs repair. Collectively, our findings describe a novel mechanism leading to PARPi resistance that involves unscheduled MUS81-dependent cleavage of intact, unreversed replication forks. Since this cleavage occurs mimicking the phosphorylated status of S87 of MUS81, our data suggest that hyperphosphorylation of this residue in S-phase might represent a novel biomarker to identify resistance to PARPi.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents* / metabolism
  • DNA Replication
  • DNA-Binding Proteins* / genetics
  • DNA-Binding Proteins* / metabolism
  • Endonucleases* / metabolism
  • Mammals / metabolism
  • Phosphorylation

Substances

  • DNA-Binding Proteins
  • Endonucleases
  • olaparib
  • Antineoplastic Agents